MX346749B - Uso de intercambio de medio liquido por filtracion de flujo cruzado en la preparacion de suspensiones de farmaco. - Google Patents

Uso de intercambio de medio liquido por filtracion de flujo cruzado en la preparacion de suspensiones de farmaco.

Info

Publication number
MX346749B
MX346749B MX2013008118A MX2013008118A MX346749B MX 346749 B MX346749 B MX 346749B MX 2013008118 A MX2013008118 A MX 2013008118A MX 2013008118 A MX2013008118 A MX 2013008118A MX 346749 B MX346749 B MX 346749B
Authority
MX
Mexico
Prior art keywords
preparation
liquid medium
cross flow
particles
flow filtration
Prior art date
Application number
MX2013008118A
Other languages
English (en)
Other versions
MX2013008118A (es
Inventor
Hans Peter Niedermann
Heiko Bothe
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2013008118A publication Critical patent/MX2013008118A/es
Publication of MX346749B publication Critical patent/MX346749B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Abstract

Se describe un método para hacer partículas de un fármaco, en donde se hace uso de la diafiltración; la diafiltración puede ser con un antisolvente, en cuyo caso se obtiene un precipitado de partículas como tales; la diafiltración también puede ser con un medio de suspensión farmacéuticamente aceptable; en ese caso se pueden evitar varios pasos del proceso de aislar, secar, transportar partículas, porque la suspensión que resulta de la síntesis de las partículas se dirige directamente a una formulación final del producto del fármaco.
MX2013008118A 2011-01-12 2012-01-11 Uso de intercambio de medio liquido por filtracion de flujo cruzado en la preparacion de suspensiones de farmaco. MX346749B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161431942P 2011-01-12 2011-01-12
PCT/EP2012/050336 WO2012095439A1 (en) 2011-01-12 2012-01-11 Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions

Publications (2)

Publication Number Publication Date
MX2013008118A MX2013008118A (es) 2013-08-12
MX346749B true MX346749B (es) 2017-03-29

Family

ID=45478323

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008118A MX346749B (es) 2011-01-12 2012-01-11 Uso de intercambio de medio liquido por filtracion de flujo cruzado en la preparacion de suspensiones de farmaco.

Country Status (10)

Country Link
US (1) US9066864B2 (es)
EP (1) EP2663287A1 (es)
JP (1) JP5934719B2 (es)
CN (1) CN103347499B (es)
AU (1) AU2012206621B2 (es)
BR (1) BR112013016851B1 (es)
CA (1) CA2823972C (es)
MX (1) MX346749B (es)
SG (2) SG10201807631SA (es)
WO (1) WO2012095439A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6478959B2 (ja) * 2016-09-07 2019-03-06 株式会社富士薬品 粒子含有組成物を製造するためのシステム及び方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340580B1 (en) 1999-05-12 2002-01-22 Metabolix, Inc. Methods for purifying polyhydroxy alkanoates
WO2001021290A1 (en) * 1999-09-17 2001-03-29 Danish Separation Systems As A method and an apparatus for continuous cross-flow diafiltration
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
EP1458365A1 (en) * 2001-12-21 2004-09-22 Celator Technologies Inc. Improved polymer-lipid delivery vehicles
WO2003063877A1 (en) 2002-02-01 2003-08-07 Akzo Nobel N.V. Cefquinome composition for intra-mammary administration in cattle
JP4584715B2 (ja) * 2002-10-25 2010-11-24 インターベツト・インターナシヨナル・ベー・ベー 持続放出性医薬組成物
ITMI20022674A1 (it) 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
TR201906255T4 (tr) * 2009-12-11 2019-05-21 Pfizer Terapötik partiküllerin liyofilize edilmesine yönelik stabil formülasyonlar.

Also Published As

Publication number Publication date
CA2823972C (en) 2019-05-28
AU2012206621B2 (en) 2017-04-27
CN103347499A (zh) 2013-10-09
SG10201807631SA (en) 2018-10-30
BR112013016851A2 (pt) 2016-10-04
WO2012095439A1 (en) 2012-07-19
BR112013016851B1 (pt) 2021-08-31
SG191963A1 (en) 2013-08-30
JP5934719B2 (ja) 2016-06-15
EP2663287A1 (en) 2013-11-20
US20130281425A1 (en) 2013-10-24
CN103347499B (zh) 2017-04-05
CA2823972A1 (en) 2012-07-19
AU2012206621A1 (en) 2013-07-04
MX2013008118A (es) 2013-08-12
JP2014502624A (ja) 2014-02-03
US9066864B2 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
HK1200207A1 (en) Process line for the production of freeze-dried particles
SE0800304L (sv) Förfarande för framställning av etanol utifrån sockerartshaltig lösning/suspension medelst fermentering
TN2013000411A1 (en) Branched 3-phenylpropionic acid derivatives and the use thereof
WO2012094425A3 (en) Biological methods for preparing adipic acid
TN2015000104A1 (en) Novel rig-i ligands and methods for producing them
IL232662B (en) Process for producing virus-like particles comprising enterobacteriophage ms2 capsid proteins
HK1199242A1 (zh) 生產 -丁二烯的方法
EA201270409A1 (ru) Способ производства промежуточных продуктов артемизинина
IT1399862B1 (it) Macchina ad asse verticale per la produzione di sacchetti-filtro con prodotti da infusione
EP3199518A4 (en) Process for producing high-purity aqueous urea solution in urea production process
MX350430B (es) Proceso para preparar compuestos acido 4-amino-5-bifenil-4-il-2-hi droximetil-2-metil-pentanoico.
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
HRP20181274T1 (hr) Farmaceutska mješavina za pripremu infuzijskih otopina antimikrobnih pripravaka, njezin proizvodni proces
MX2013008118A (es) Uso de intercambio de medio liquido por filtracion de flujo cruzado en la preparacion de suspensiones de farmaco.
WO2012166822A3 (en) Method to produce polyhydroxyalkanoates from water-based feedstock streams
WO2015101243A8 (zh) 雌性不育系的繁殖及杂交制种技术
MY169503A (en) Preparation method of new recombinant antibacterial polypeptide medicine
WO2015124683A3 (de) Filter, verwendung des filters und dessen herstellungsverfahren
WO2013046233A3 (en) Process for the preparation of octreotide acetate
RU2012133403A (ru) Способ получения микрокапсул лекарственных препаратов группы цефалоспоринов в конжаковой камеди в бутиловом спирте
JP2014502624A5 (es)
WO2013080221A3 (en) Process for alvimopan
CA2862520A1 (en) Method for stereoselective synthesis of 1,4-protected 9-hydroxy-5-oxo-1,4-diaza-spiro[5.5]undecanes
WO2013048898A3 (en) Biological methods for preparing adipic acid
WO2013048169A3 (en) Method for preparing taxane derivatives

Legal Events

Date Code Title Description
FG Grant or registration